Letter to the Editor

Statins Unmasking a Mitochondrial Myopathy: A Case Report and Proposed Mechanism of Disease

Authors: Benjamin J. Diaczok MD, R. Shali MD

Abstract

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

References 1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307.ShepherdJ]]CobbeSM]]FordI]]IslesCG]]LorimerAR]]MacFarlanePWPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group.N Engl J Med19953331301 2. Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.Scandinavian Simvastatin Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)Lancet19943441383 3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–1009.SacksFM]]PfefferMA]]MoyeLA]]RouleauJL]]RutherfordJD]]ColeTGThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigatorsN Engl J Med19963351001 4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med19983391349 5. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J–34J.TobertJAEfficacy and long-term adverse effect pattern of lovastatinAm J Cardiol19886228J 6. Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up. Am J Cardiol 1994; 74: 667–673.BradfordRH]]ShearCL]]ChremosAN]]DujovneCA]]FranklinFA]]GrilloRBExpanded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-upAm J Cardiol199474667 Montgomery R, Conway TW, Spector AA, Chappell A. Biochemistry: A Case-Oriented Approach. St. Louis, Mosby-Year Book, 1996, ed 6. 8. Wallace DC. Mitochondrial DNA in aging and disease. Sci Am 1997; 277: 40–47.WallaceDCMitochondrial DNA in aging and diseaseSci Am199727740 9. Pravachol, in Physicians’ Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 846–849. 10. Zocor, in Physicians’ Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 1917–1920. 11. Lipitor, in Physicians’ Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 2254–2257. 12. Lescol, in Physicians’ Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 2021–2024. 13. Mevacor, in Physicians’ Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 1833–1837. 14. Baycol, in Physicians’ Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 675–677. 15. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: The role of metabolism—Monograph for physicians. Arch Intern Med 2000; 160: 2273–2280.BottorffM]]HanstenPLong-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: The role of metabolism—Monograph for physiciansArch Intern Med20001602273 16. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al (eds). Harrison's Principles of Internal Medicine. New York, McGraw-Hill Health Professions Division, 1998, ed 14.